Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.

van der Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, Wyen C, Schutz M, Koopmans P, Ruxrungtham K, Richter C, Burger D; SARA study team.

Antivir Ther. 2009;14(3):443-50.

PMID:
19474478
2.

Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

AIDS. 2000 Jun 16;14(9):F103-10.

PMID:
10894270
3.

Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.

Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Schreij G, van der Geest S, Lange JM, Beijnen JH, Hoetelmans RM.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):344-9.

PMID:
11468422
4.

Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.

von Hentig N, Nisius G, Lennemann T, Khaykin P, Stephan C, Babacan E, Staszewski S, Kurowski M, Harder S, Haberl A.

Antivir Ther. 2008;13(8):1039-46.

PMID:
19195329
5.

Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.

Martinez-Rebollar M, Lonca M, Perez I, Soy D, Brunet M, Martin R, Coll O, Hernandez S, Laguno M, Milinkovic A, Larrousse M, Calvo M, Blanco JL, Martínez E, Gatell JM, Mallolas J.

Ther Drug Monit. 2011 Dec;33(6):772-7. doi: 10.1097/FTD.0b013e318236376d.

PMID:
22105596
6.

Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.

Cardiello PG, Monhaphol T, Mahanontharit A, van Heeswijk RP, Burger D, Hill A, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P.

J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):375-9.

PMID:
12640194
7.

Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.

Cameron DW, Becker S, King MS, da Silva B, Klein C, Tokimoto D, Foit C, Calhoun D, Bernstein B, Hanna GJ.

J Antimicrob Chemother. 2007 May;59(5):957-63. Epub 2007 Mar 9.

PMID:
17350990
9.

Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A.

Ther Drug Monit. 2007 Apr;29(2):171-6.

PMID:
17417070
10.

Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J; HIV-NAT 017 Study Team.

Antivir Ther. 2009;14(2):241-8.

PMID:
19430099
11.

Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.

Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J; HIV-NAT 017 Study Team.

Pediatr Infect Dis J. 2008 Jul;27(7):623-8. doi: 10.1097/INF.0b013e31816b4539.

PMID:
18520443
12.

Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.

Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A.

J Antimicrob Chemother. 2005 Apr;55(4):542-5. Epub 2005 Feb 18.

PMID:
15722388
13.

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.

J Antimicrob Chemother. 2007 Apr;59(4):690-7. Epub 2007 Feb 16.

PMID:
17307771
14.

Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.

Rolla VC, da Silva Vieira MA, Pereira Pinto D, Lourenço MC, de Jesus Cda S, Gonçalves Morgado M, Ferreira Filho M, Werneck-Barroso E.

Clin Drug Investig. 2006;26(8):469-79.

PMID:
17163279
16.

The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.

Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba AD.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):921-8.

PMID:
15220698
17.

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1376-84.

PMID:
15483467
18.

Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G, Nelson M, Tomkins J, Gazzard B, Pozniak A.

Br J Clin Pharmacol. 2005 Jan;59(1):38-42.

19.

Dose reduction effective in alleviating symptoms of saquinavir toxicity.

Stephan C, Carlebach A, Rottmann C, Haberl A, Dauer B, von Hentig N, Kurowski M, Staszewski S.

Int J STD AIDS. 2007 Feb;18(2):81-4.

PMID:
17331276
20.

Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.

Autar RS, Wit FW, Sankote J, Sutthichom D, Kimenai E, Hassink E, Hill A, Cooper DA, Phanuphak P, Lange JM, Burger DM, Ruxrungtham K.

AIDS. 2007 Jul 31;21(12):1535-9.

PMID:
17630547

Supplemental Content

Support Center